Editor's note: Adam Feuerstein's columns run exclusively on
; this is a special free look at his column. For a free trial subscription to RealMoney.com, please
Back in July, after polling a group of trusted health care fund managers, I called
one of the
in the biotech sector. Why? Because of the widely held belief that the trials of its experimental antisense cancer drug Genasense would fail, but Genta would nonetheless find something positive to say. That may throttle short-sellers, who now control 28% of the company's freely traded shares.
It seems like that prediction has come true.
Genta said Wednesday that Genasense failed to significantly extend overall survival in patients with advanced skin cancer, according to results from a large, phase III clinical trial.
But despite the negative results shown in the study's primary endpoint, Genta is claiming victory and says it is filing the drug for approval with the Food and Drug Administration.
The question left unanswered is what happens to Genta's stock today. Will investors believe the company's spin? Or will they look at the Genasense data and note that the melanoma study's primary endpoint -- the most important, clinically relevant goal of the study -- came up way short?
Genta has always been a battleground stock between longs and shorts. Wednesday's announcement is only going to intensify the fighting, which I reckon will go on for a long time.
A Look at the Results
Let's get right to the data, starting with the most important goal of the melanoma study: the primary endpoint of overall survival.
By the generally accepted statistical measures of efficacy, the Genasense study, enrolling 771 patients on an intent-to-treat basis, was a failure. Melanoma patients who received a combination of Genasense and chemotherapy survived an average of 9.1 months. Patients receiving just chemotherapy survived 7.9 months. That's an increase in survival of just over one month in favor of Genasense.